Nurix Therapeutics, Inc.

NRIX · United States

Share price · NRIX

$14.10-12.83 (-47.64%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.8M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NRIX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026-38.2%
  2. 14 Oct 2026+7.0%
  3. 25 Jun 2026+16.4%
  4. 11 Jun 2026+11.0%
  5. 8 Jun 2026+6.8%
  6. 3 Jun 2026-5.4%
  7. 21 May 2026+6.8%
  8. 28 Apr 2026+3.6%
  9. 8 Apr 2026-4.6%
  10. 8 Dec 2025+18.7%

Share of unusual movement by asset

For each asset, the share of NRIX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
bexobrutideg
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—36%
Sessions with no dated event—61%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Bruton's tyrosine kinase (BTK)Small molecule
Chronic Lymphocytic Leukemia
Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 1
Cbl-bSmall molecule
Non-Small Cell Lung Cancer

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
bexobrutidegPhase 2Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Est. primary completion 2028-01 · NCT07221500 · CT.gov ↗
What to watch
2029 (1)
October 2029 (1)
bexobrutidegPhase 3B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Est. primary completion 2029-10 · NCT07516093 · CT.gov ↗
What to watch
2033 (1)
May 2033 (1)
bexobrutidegPhase 1/2B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Est. primary completion 2033-05 · NCT07520006 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$673M$79M$720M+ $328M short-term inv.—$616M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$88M$68M+ $376M short-term inv.$90M-$97M operating cash flowreport ↗
2026-Q1—$84M$71M+ $470M short-term inv.$87M-$72M operating cash flowreport ↗
2025-Q3—$86M$78M+ $350M short-term inv.$86M-$57M operating cash flowreport ↗
2025-Q2—$78M$84M+ $402M short-term inv.$43M-$63M operating cash flowreport ↗
2025-Q1—$70M$76M+ $474M short-term inv.$56M-$61M operating cash flowreport ↗
2024-Q3—$55M$99M+ $349M short-term inv.$49M-$42M operating cash flowreport ↗
2024-Q2—$49M$117M+ $326M short-term inv.$45M-$40M operating cash flowreport ↗
2024-Q1$17M$50M$50M+ $194M short-term inv.$42M-$42M operating cash flowreport ↗
2023-Q3$18M$48M$42M+ $217M short-term inv.$37M-$41M operating cash flowreport ↗
2023-Q2$31M$46M$59M+ $222M short-term inv.$24M-$18M operating cash flowreport ↗
2023-Q1$13M$46M$34M+ $244M short-term inv.$41M-$48M operating cash flowreport ↗
2022-Q3$11M$48M$48M+ $297M short-term inv.$46M-$46M operating cash flowreport ↗
2022-Q2$11M$47M$42M+ $256M short-term inv.$45M-$33M operating cash flowreport ↗
2022-Q1$9.6M$43M$79M+ $183M short-term inv.$43M-$43M operating cash flowreport ↗
2021-Q3$10M$31M$147M+ $196M short-term inv.$29M-$30M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$317M$247M+ $346M short-term inv.$66M-$249M operating cash flowreport ↗

For fiscal year 2025, Nurix Therapeutics did not disclose revenue. Research and development spend was $316.9M, up 43.0% YoY, and the company reported cash and equivalents of $246.96M with a net loss of $264.46M.

Nurix is a clinical-stage biopharmaceutical company advancing targeted protein degradation medicines. In October 2025, it initiated a potentially pivotal Phase 2 study of bexobrutideg in relapsed/refractory CLL, while continuing Phase 1a/1b studies for zelebrudomide and NX-1607. Partnered programs with Gilead, Sanofi, and Pfizer advanced, including FDA clearance of an IND for GS-6791/NX-0479 and Sanofi licensing NX-3911; collaborations have generated $482.0M in non-dilutive funding to date, with up to $6.1B in potential future fees and milestones.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$222M$110M+ $500M short-term inv.$48M-$173M operating cash flowreport ↗
2023-FY$77M$189M$55M+ $233M short-term inv.$36M-$81M operating cash flowreport ↗
2022-FY$39M$185M$64M+ $245M short-term inv.$45M-$160M operating cash flowreport ↗
2021-FY$30M$116M$81M+ $215M short-term inv.$29M-$84M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 48 sales ($5.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-04van Houte Hans · Chief Financial OfficerOpen-market sale3,300$15.38$51KForm 4
2026-11-04van Houte Hans · Chief Financial OfficerOpen-market sale1,469$16.20$24KForm 4
2026-11-03Ring Christine · Chief Legal OfficerOpen-market sale6,113$25.83$158KForm 4
2026-11-02Ring Christine · Chief Legal OfficerOption exercise5,786$8.72$50KForm 4
2026-11-02Ring Christine · Chief Legal OfficerOpen-market sale9,527$25.74$245KForm 4
2026-11-02Ring Christine · Chief Legal OfficerOpen-market sale1,075$26.76$29KForm 4
2026-11-02Ring Christine · Chief Legal OfficerOption exercise (derivative)5,786——Form 4
2026-11-02Hansen Gwenn · Chief Scientific OfficerOption exercise1,452$1.86$3KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 194 reporting institutions held 117.3M shares ($1.8B, 107.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.8,925,642$138.3M
2Redmile Group, LLC7,732,808$119.9M
3Vestal Point Capital, LP6,500,000$100.8M
4Deep Track Capital, LP6,345,244$98.4M
5FMR LLC5,541,271$85.9M
6STATE STREET CORP5,141,195$79.7M
7MORGAN STANLEY4,931,999$76.4M
8BAKER BROS. ADVISORS LP4,658,556$72.2M
9VANGUARD CAPITAL MANAGEMENT LLC4,427,112$68.6M
10GENERAL ATLANTIC, L.P.4,101,865$63.6M
11PERCEPTIVE ADVISORS LLC3,710,877$57.5M
12Pictet Asset Management Holding SA2,726,138$42.3M
13GEODE CAPITAL MANAGEMENT, LLC2,520,229$39.1M
14Rubric Capital Management LP2,473,885$38.3M
15DEUTSCHE BANK AG\2,295,024$35.6M